4

PRIMARY DOCUMENT

Company: REGENERON PHARMACEUTICALS, INC.
Filed: May 17, 2023
Period of Report: May 15, 2023
Accession Number: 0001883850-23-000069

View Document ↗ View on SEC.gov ↗